Cancer Drug Development · global
Two T-cell engagers combined show 29% response rate in early uveal melanoma trial
Immunocore reported combination therapy results in 17 evaluable first-line patients, with an estimated two-year overall survival rate of 70%. This small study provides a rationale for further validation, but whether the combination can outperform existing treatment remains a question for randomized trials.
Can drugs that direct immune cells toward tumors take treatment further by targeting two different targets at once? On November 6, Immunocore announced early trial results in metastatic uveal melanoma: the investigational drug brenetafusp combined with Kimmtrak produced an objective response rate of 29% in 17 evaluable first-line patients. This provides an initial clinical signal for the two-drug strategy, but is not yet sufficient to establish that adding the drug can extend life.
Both drugs are T-cell engagers that recognize antigen signals presented by cancer cells and bring T cells to the tumor to launch an attack. Tebentafusp, the active ingredient in Kimmtrak, targets gp100, while brenetafusp targets PRAME. The study aims to broaden opportunities for attack through two different targets; whether this approach actually delivers additional benefit is precisely what subsequent trials will need to establish.
The data come from IMC-F106C-101, a first-in-human Phase 1/2 trial primarily exploring safety, dosing, and preliminary antitumor activity. According to the company's third-quarter business update released the same day, as of June 2026, 26 patients had received the combination, and another 22 had received brenetafusp monotherapy at clinically active doses. These patients with metastatic uveal melanoma were all HLA-A*02:01-positive, so the results cannot be directly generalized to all patients.
Among the 17 evaluable patients receiving the combination as first-line treatment, median duration of response was 24.1 months and median progression-free survival was 8.1 months. The former describes how long responses lasted among those who responded to treatment; it does not mean that everyone treated can achieve two years of tumor control. At a median follow-up of 29 months, median overall survival had not been reached, and the estimated two-year overall survival rate was 70%.
On safety, the company said the most common treatment-related adverse events with the combination were Grade 1 to 2 cytokine release syndrome and rash, each occurring in 77% of patients. The study reported no Grade 3 or higher cytokine release syndrome and no discontinuations or deaths due to treatment-related adverse events. However, the limited number of participants still makes it difficult to rule out less common or later-emerging risks.
The most important limitations when interpreting efficacy are the small sample and the absence of a randomized control group. Patients' disease characteristics and subsequent treatments could both affect survival outcomes; the 70% two-year survival rate is also only an estimate for this group of participants and cannot establish superiority over Kimmtrak monotherapy. The study also reported later-line monotherapy data, but differences in treatment line and patient composition likewise make direct comparisons of the two approaches inappropriate.
These results were presented as a poster on November 6 at the Society for Immunotherapy of Cancer (SITC) annual meeting, with an oral presentation scheduled for November 7. Immunocore plans to initiate the randomized Phase 2/3 DUET-UVEAL trial to further evaluate the combination. The current data support taking the question into a more rigorous trial; evidence capable of changing treatment choices will still require confirmation that the benefit of adding a drug is sufficient to outweigh the additional treatment burden and risks.